SCHEMBL7527206

SCHEMBL7527206

CCOP(=O)(O)c1cc(-c2ccc(C)cc2)ccc1OC

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.41
▸ HPGD P15428 1/20 0.41
▸ LMNA P02545 1/20 0.38
▸ PKM P14618 1/20 0.38
▸ CTNNB1 P35222 1/20 0.38
▸ WNT3A P56704 1/20 0.38
▸ CTSA P10619 2/20 0.37
▸ FDPS P14324 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ L3MBTL1 Q9Y468 2/20 0.36
▸ PTPN5 P54829 1/20 0.36
▸ TP53 P04637 1/20 0.36
▸ THRB P10828 1/20 0.36
▸ GAA P10253 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ ACHE P22303 1/20 0.35
▸ HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7188821 0.85 CFD (0.41) ALDH1A1HPGDLMNACTSAFDPS
SCHEMBL7527451 0.85 ALDH1A1 (0.39) ALDH1A1LMNAL3MBTL1
SCHEMBL7193757 0.85 ALDH1A1 (0.50) ALDH1A1FDPSGAA
SCHEMBL7183106 0.83 POLB (0.46) ALDH1A1FDPSMAPTPTPN5
SCHEMBL7182889 0.81 ALDH1A1 (0.46) ALDH1A1FDPSHTT
SCHEMBL7190208 0.81 ALDH1A1 (0.41) ALDH1A1HPGDFDPS
SCHEMBL7597971 0.79 ALDH1A1 (0.34) ALDH1A1HPGDLMNAFDPS
SCHEMBL7527196 0.76 ALDH1A1 (0.43) ALDH1A1HPGDLMNAPKMCTNNB1
SCHEMBL16868513 0.74 ALDH1A1 (0.68) ALDH1A1LMNAMAPTL3MBTL1HTT
SCHEMBL7180293 0.74 PLA2G2D (0.40) ALDH1A1HPGDLMNAPTPN5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6486141-B2 TREATING OR PREVENTING PTP-1B MEDIATED DISEASES, INCLUDING DIABETES, OBESITY, AND DIABETES-RELATED CONDITIONS. MERCK FROSST CANADA & CO. (CA) 2002-11-26 — — US disclosed
EP-1244677-A1 PHOSPHONIC ACID BIARYL DERIVATIVES AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE 1B (PTP-1B) MERCK FROSST CANADA INC. (CA) 2002-10-02 — — EP disclosed
US-20020052346-A1 Phosphonic acid biaryl derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B) MERCK FROSST CANADA LTD. (CA) 2002-05-02 — — US disclosed
WO-2001046203-A1 PHOSPHONIC ACID BIARYL DERIVATIVES AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE 1B (PTP-1B) MERCK FROSST CANADA & CO. (CA) 2001-06-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020052346-A1 Phosphonic acid biaryl derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B) PTPRO, PPM1B, PTPA ALDH1A1 600/4885HPGD 2990/4885LMNA 4443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback